Fatemeh Safari
Mohammad Hossein Ahmadi
Mehdi Azad
Neda Karami
Amirhosein Maali
Neda Mohammadi
Ali Homaei
Farshad Foroughi

Abstract

Objective:

Hashimoto’s thyroiditis (HT) is an autoimmune thyroid disease characterized by thyroid-specific autoantibodies. Recent studies have shown the critical footprint of DNA methylation in autoimmune diseases. The aberrant DNA methylation of CTLA4 has been previously reported in autoimmune thyroid diseases. This study aimed to investigate the methylation status of the CpG island of CTLA4 promoter and its mRNA expression level in HT patients.

Materials and Methods:

In this case-control study, 45 HT patients (admitted to Qods Hospital, Qazvin, Iran) and 5 healthy individuals participated. After RNA and DNA extractions, the DNA methylation pattern of the CpG island of CTLA4 promoter and CTLA4 mRNA expression level were evaluated. All statistical analyses were performed using SPSS ver 20.

Results:

Our results indicated partial hypermethylation status in the CpG island of CTLA4 promoter in HT patients compared to normal individuals, but this hypermethylation was not significantly higher (p=0.332). The mRNA expression level of CTLA4 was significantly decreased in HT patients compared to that of controls (Foldchange=0.31, p=0.015). Also, serum level of anti-TPO antibody was not significantly correlated with CTLA4 expression level and its methylation status.

Conclusion:

Since the CTLA4 acts as an immune checkpoint that leads to the downregulation of immune response, partial hypermethylation and downregulation of CTLA4 may play a critical role in preventing switching off the immune response after a hyperactivation against the thyroid.

Keywords:

Autoimmune diseases, Hashimoto disease, CTLA4, DNA methylation, gene expression

VOLUME

11

,

ISSUE

1
April 2023

Correspondence

Farshad Foroughi

Email

farshad295@yahoo.com

Received

Accepted

Published

Suggested Citation

DOI

License

This work is licensed under the Creative Commons Attribution-NonCommercial-Non-Derivatives 4.0 International License (CC BY-NC-ND 4.0). License